LGL from both leukemic and BMT donors spontaneously developed an ex vivo CTL-like CD3-redirected cytotoxicity but no NK cell activity. Different stimuli (PHA, PMA or rhIL-2) induced similar cytotoxic profiles after a 6-day culture involving a CD3-redirected lysis predominating over a low NK cell activity. However, culture of leukemic LGL with these stimuli allowed either a 2 week persistence (PMA or rhIL-2) of CD8 ؉ CD57 ؉ LGL or their disappearance after 3 days (PHA). Furthermore, leukemic CD8 hi؉ CD57 ؉ T lymphocytes produced an inhibitor of cytotoxic functions as previously described for BMT recipients' CD8 ؉ CD57 ؉ cells. Thus, despite some phenotypic differences between both cell sources, leukemic CD57 ؉
Introduction
Increased numbers of circulating large granular lymphocytes (LGL) were recognized as a distinct clinical entity in 1977, and this syndrome was characterized by clonal lymphocytosis and tissue invasion. 1 In light of the evidence that clonal LGL proliferations may be either of T cell origin and express the TCR-CD3 complex, or of NK cell origin and are CD3 − cells, the following terminology was adopted: (1) T-LGL leukemia, characterized by clonal CD3
LGL proliferation; (2) NK-LGL leukemia, characterized by clonal CD3
LGL proliferation. 2 T-LGL leukemia follows a chronic course during which major features are neutropenia, anemia, bone marrow infiltration and mild to moderate splenomegaly. Multiple immune abnormalities are frequent (presence of rheumatoid factor, and/or autoimmune antibodies, polyclonal hypergammaglobulinemia and circulating immune complexes). Rheumatoid arthritis coexists in 28% of patients, who thus resemble patients with Felty's syndrome. 3 As T-LGL expansions can display an heterogeneous phenotype, [4] [5] [6] in this report we will focus on the non-aggressive and most frequent CD3
CD57
+ T-LGL leukemia, ie negative for CD56 and positive for CD8. 3 Perforin, a cytolytic molecule responsible for pore formation in target cells, and TiA-1, a membrane protein from cyto- lytic granules, were both present in several cases of T-LGL leukemia 7, 8 suggesting a lytic potential. Furthermore, FasL, predominantly expressed on and secreted by activated T cells, 9 is constitutively expressed by these leukemic cells and sera from LGL leukemic patients contain detectable levels of sFasL, while sera from healthy persons do not. 10, 11 While no spontaneous NK cell activity is usually observed, 5 T-LGL leukemic cells can be stimulated after a 24-48 h culture by anti-CD3 Ab or rhIL-2 to acquire NK cell cytotoxicity against K562 target cells. 6, 12, 13 However, the capacity of their CD3 complex to transduce a signal for cytolysis has not been directly evaluated on sorted unstimulated CD8
LGL. An impairment of T cell proliferative responses to mitogens such as phytohemagglutinin A (PHA) 14 has also been reported as well as a defect in the formation of high-affinity IL-2 receptors, 12 despite constitutive expression of functional p75 intermediate-affinity IL-2 receptors. 13, 15 However, these leukemic LGL cannot be considered as anergic cells since they can also proliferate in vitro after the combinative signal of anti-CD3 and either IL-2 or IL-4 16 and can be maintained in long-term cultures for as long as 1 or 2 months. 17 CD3 + LGL leukemia are also highly sensitive to the combined stimulation by anti-CD3 + rhIL-12, mediated by upregulation of IL-12 receptor upon anti-CD3 ligation. 18 Taken together, these results show that leukemic T-LGL can proliferate after activation through their CD3-TCR complex in the presence of exogenous lymphokines.
Since leukemic CD3 + T-LGL usually display the CD57 marker, we postulated that their normal counterpart might be the CD3 + CD8 + CD57 + T lymphocytes. This normal subset is frequently expanded in vivo after chronic antigen-specific stimulation of CD8 + T cells due to viral infections (human immunodeficiency virus (HIV) or cytomegalovirus (CMV) ) or allogenic transplantations and displays the cytological characteristics of LGL. [19] [20] [21] [22] [23] In this case, these expanded cells are not clonal although a remarkable restriction of the TCR V␤ usage by CD8
+

CD57
+ cells could be evidenced after BMT. 24 A similar oligoclonality of the expanded peripheral CD8 +
+ subset has recently been confirmed in CMV-infected patients. 25 Both findings were suggestive of an antigen-driven skewing of the TCR repertoire in these cells. Thus, based on their cytological features, CD3 +
CD8
+ CD57 + T cells appear as the normal counterpart of the leukemic CD3 +
CD57
+ LGL, although their functional characteristics have never been compared until now. Our group and others showed that non-leukemic CD8 +
+ lymphocytes mediate immunoregulatory functions. Indeed, the CD8 +
+ cells, initially reported to down-modulate B cell differentiation and CD4
+ T cell proliferation, inhibit the CD8 + T cell or NK cell cytotoxic activity. 19, 21, [26] [27] [28] [29] Our group further showed that CD8
T cells mediate this inhibitory activity by releasing a soluble 30 kDa glycoprotein (ICF). 19 In contrast, they can also mediate a killer cell activity after non-specific activation, [30] [31] [32] and we recently showed their capacity to develop a peptide-specific cytotoxicity. 33 Furthermore, during CMV infection CMVspecific CTL precursors could be detected both in the CD57 + 
and CD57
− CD8 + subsets. 25, 34 Therefore we raised the question whether: (1) the CD8 +
CD57
+ leukemic T-LGL were an homogeneous subset with regards to their phenotypic and functional features as compared to autologous CD8 +
− lymphocytes; and (2) these leukemic CD8 + CD57 + T-LGL share characteristics with the non-leukemic CD8 +
+ T cell subset amplified in vivo after BMT. Thus, we first characterized the phenotypic status of the LGL leukemic cells in order to compare them with BMT recipients' CD8 +
+ cells. Then the aim of this study was to define more precisely the cytotoxic and proliferative capacities of the clonal LGL leukemic CD8 +
+ cells in response to either a CD3-triggering, a phosphokinase C (PKC) stimulation or an rhIL-2 activation.
Patients and methods
Patients
We studied four patients who met the criteria for diagnosis of CD3 + LGL leukemia with lymphocyte counts from 2200 to 15 600/l (compared with normal: 1500 to 4000/l), and had evidence of clonal rearrangement of the T cell receptor beta gene (Southern blot detection). Their major clinical features are summarized in Table 1 .
Four allogenic HLA-matched BMT recipients were studied following BMT from an HLA-identical sibling for hematologic malignancies or severe aplastic anemia.
HIV-seronegative blood bank donors were tested as controls. 
Peripheral blood lymphocyte isolation and cell culture
Whole blood was washed in PBS (Gibco, Paisley, UK) and lymphocytes were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient centrifugation. PBL (1 × 10 6 cells/ml) were stimulated with either 100 units/ml of rhIL-2 (Boehringer Mannheim, Mannheim, Germany), PHA-P 1 g/ml (Sigma, Saint-Quentin, France) + rhIL-2 20 U/ml or PMA 1 ng/ml (Sigma) + rhIL-2 20 U/ml and cultured in RPMI 1640 culture medium (ICN Flow, Irvine, UK) supplemented with 10% FCS (Gibco), 1 mm sodium pyruvate (Gibco), 2 mm l-glutamine (Gibco), 1% MEM non-essential amino acids (Gibco). At day 4 and every 3 days, rIL 2 (20 U/ml) was added.
Immunofluorescence analysis
Cell surface antigens were characterized using a standard staining method with the following monoclonal antibodies (mAbs): 
Cell sorting procedures
Immunomagnetic separations of CD8 +
CD57
+ lymphocytes were performed on fresh PBL from CD3 + LGL leukemic patients. Avidin-conjugated magnetic beads (Immunotech) were coupled with biotinylated CD57 mAb as previously described. 19, 35 Cell suspensions were added to these complexes and mixed gently for 45 min at 4°C and CD57
+ cells isolated by applying a cobalt magnet (Dynal, Oslo, Norway). The CD57 positive and negative cell fractions contained Ͼ90% and Ͻ10% of CD8 hi+ CD57 + cells, respectively. Both fractions were used on the one hand to produce supernatant as described below, and on the other hand, after bead removal, as effectors in chromium release assays (CRAs) at day 3 and day 7. The beads spontaneously detached from the positive fraction after 24 h of culture following the selection process, and were removed by applying a magnet.
Fluorescence-activated cell sorting was performed on PBMC from BMT recipients resuspended in RPMI 1640 medium at 10 × − subsets were restricted to a lymphocyte scatter gate. The purity and viability of each sorted subpopulation was always greater than 95%.
Production and concentration of ICF
Supernatants (SN) were prepared as described 19, 35 from immuno-bead purified CD8
. Bead-attached cells and control cells were resuspended at 5 × 10 6 cells/ml in serum-free culture medium (RPMI 1640 supplemented with 1 mm sodium-pyruvate, 2 mm l-glutamine), without stimulation and incubated for 4 and 18 h at 37°C. Cell suspensions were then centrifuged at 400 g. Resulting SN were ultracentrifugated at 3000 g for 1 h at 4°C using Centricon-10 concentrators (Amicon, Epernon, France) before high speed freezing and storage at −20°C. Concentrations obtained were 4× to 10×.
Cytolytic assay
PBL from CD3
+ LGL leukemic patients were tested without pre-activation and at day 6 of stimulations described before (PHA-P + rhIL-2 20 U/ml, PMA + rhIL-2 20 U/ml, rhIL-2 100 U/ml). LAK cells were obtained at day 3 of an initial stimulation with 100 U/ml of rhIL-2 from seronegative donors' PBL as described above. Target cells used were P815 for CD3-redirected assay, K562 for NK cell lysis and Daudi for LAK cell cytotoxicity. They were incubated for 2 h with 80 Ci/10 6 cells of Na 51 2 Cr0 4 (Amersham, Les Ulis, France). Suspensions of 3000 target cells were added in triplicate to round-bottom 96-well microtiter plates (Costar, Cambridge, MA, USA). In the CD3-redirected assays, UCHT1 (ascitic fluid kindly provided by Pr Beverley, London, UK) was added to P815 target cells at dilutions of 1/4000. After a 4-h incubation at 37°C, supernatants were collected and the chromium release was measured on a ␥-counter (LKB, Pharmacia). The values of spontaneous chromium release were 10-20% of total incorporated radioactivity.
Inhibition of cytolytic activity was analyzed after a 1-h preincubation of effector cells with CD8
, prior to the cytolytic assay. The cytolytic assay was performed as described above at a constant LAK/Daudi ratio ensuring a 20-30% specific lysis ± anti-IFN-␥ (8 g/ml, R&D Systems, Abingdon, UK) ± anti-IL-4 (2 g/ml, R&D Systems) were added. The percentage of chromium release inhibition was calculated as follows: percentage = 1 − [(experimental − spontaneous release/total radioactivity − spontaneous release) × 100].
BrdU proliferation assay 10 6 PBMC were incubated in 24-well flat-bottom plates in either 1 ml of complete medium, or with 100 U/ml rhIL-2 (Boehringer Mannheim). After a 3-day culture at 37°C, BrdU (30 g/ml) was added to each well for 1 h. The whole staining steps were carried out at room temperature. After harvesting, cells were washed in PBS/0.5% BSA and resuspended in 100 l of PBA-BSA for extracellular staining (20 min) with CD8-PE-Cy5 and CD57-PE. After washing in PBS-BSA, cells were incubated for 20 min in 500 l of PFA 4%, washed with PBS/0.5% BSA/0.1% saponin (Sigma) and resuspended in 100 l of the latter solution for permeabilization. DNA was fragmented with 50 U of DNAse I in 1 ml of PBS containing 5 mm of MgCl 2 . Cells were washed with PBS/0.5% BSA/0.1% saponin, and labelled for 30 min with anti-BrdU-FITC in 50 l of the latter solution. Five thousand events were analyzed on a flow cytometer (FACScalibur; Becton Dickinson) equipped with an argon ion laser exciting fluorochromes at 488 nm, three filters (FL1, BP 530 nm ± 15 nm; FL2, BP 585 ± 21 nm and FL3, LP 670 nm) and the Cell Quest software.
H-thymidine proliferation assay
Total PBMC were incubated in supplemented RPMI + 10% FCS at 5 × 10 4 cells/wells with various stimuli. We tested the proliferative effects of PHA-P (1 g/ml) + rhIL-2 (20 U/ml), PMA (1 ng/ml) + rhIL-2 (20 U/ml), coated anti-CD3 (UCHT1) + rhIL-2 (20 U/ml), and various doses of rhIL-2 (0, 20 and 100 U/ml; Boehringer). At day 3, cultures were pulsed overnight with 1 Ci/well ( 3 H-thymidine; Amersham, Les Ulis, France), harvested on filtermats (Pharmacia) and radioactivity was measured on a ␤ scintillation counter (Beckman, Gagny, France). Results are evaluated as c.p.m. quintuplicates.
TNF-␣ secretion assay
TNF-␣ secretion was measured by ELISA (R&D Systems) according to the manufacturer's procedure. Briefly, quantifications were made in 3-day culture SN from PBL either spontaneously or after stimulation of 1 × 10 6 cells/ml by anti-CD3 (UCHT1). Collected SN were centifuged and frozen until use. The sensitivity of this assay was 4.4 pg/ml. − cells with a strong heterogeneity on this latter subset (ranges 44-94%). When focusing on early activation markers, we noticed that both CD8
+ populations were negative for the IL-2 receptor CD25 and the transferrin receptor CD71, while both subsets displayed intracellular CD69 (data not shown). CD8 hi+ CD57
+ LGL strongly displayed CD38, the ␤2 integrins CD11a,b,c, and adhesion molecules CD54, CD58 (Table 2) , the late activation markers HLA-DR (data not shown) with some inter-patient variations, and were CD45RA positive but CD45RO negative (Table 2) . A strong heterogeneity was observed for CD28 expression on CD8
+ cells, with ranges from 0 to 41% positivity (data not shown).
We then compared these CD8 hi+ CD57 + leukemic cells with the minor CD8 hi+ CD57
+ cells detected in normal donors and the CD8 hi+ CD57 + cells expanded in BMT recipients (Table 2 ). In these three groups of donor cells, CD8 hi+ CD57
+ lymphocytes were CD18 + CD11a + and CD62L − without any significant percentage differences. We have previously shown that the non-leukemic CD8 + CD57 + cells from BMT recipients lack CD16 expression. 36 Interestingly enough, adhesion molecules CD11c (P = 0.007), CD54 (P = 0.03), CD58 (P = 0.001), and activation markers HLA-DR (P = 0.009), CD38 (P = 0.02) and CD45RA (P = 0.002) were over-expressed on CD8 hi+ CD57 + leukemic cells as compared to BMT recipients' CD8 hi+ CD57
+ cells while CD45RO (P Ͻ 0.0001) was down-modulated (Table 2 , and data not shown). Except for CD11b (P = 0.012) which is broadly expressed on leukemic cells, the same observations were made when comparing CD8 hi+ CD57 + cells from leukemic patients and from normal donors, although the differences in HLA-DR (P = 0.001), CD38 (P = 0.0003) and CD45RA (P Ͻ 0.0001) expression were more significant ( Table 2 , and data not shown).
Then we compared the expression of the molecules defined above on CD8 hi+ CD57
+ and CD8 hi+ CD57 − lymphocytes from the three categories of donors. Very few differences were observed between the CD57 + and CD57 − leukemic subsets, except for the CD45 isoform. Indeed, almost all CD8 hi+ CD57 + leukemic LGL were CD45RA positive (97%) and CD45RO negative as stated above, thus contrasting with a lower positivity for CD45RA in the CD57 − subset (78%, P = 0.0038) and a higher positivity for CD45RO (4%, P = 0.0113). The same CD45 isoform distribution was observed on BMT recipients' cells, although differences between CD57
+ and CD57 − subsets were less obvious. Two other significant differences were observed between CD57 + and CD57 − subsets but only on BMT recipients' cells and not on leukemic LGL: overexpression of CD11b (P = 0.01) and CD58 (P = 0.004) was observed on CD57
+ and on CD57 − cells, respectively (Table  2) .
Therefore, the leukemic CD3 To characterize the cytotoxic potential developed ex vivo by these CD3
+ LGL leukemic cells, fresh PBMC from three patients (DC, MR, DL, but not enough cells were available for patient AD to perform this study) were tested in a CD3-redirected cytolytic assay against the murine Fc-receptor bearing mastocytoma P815 target cells. A high dose-dependent CTL-like cytotoxicity was observed for the three patients' uncultured PBMC. In contrast, no NK and LAK cell activities were detectable at day 0 (Figure 1a) . Of note, PBMC from patient DL who had developed rheumatoid arthritis (Table 1) behaved similarly to the other two patients' cells. Interestingly, the CD3 triggering of total LGL also induced a potent TNF-␣ production (Ͼ1000 pg/ml) although the serum levels of TNF-␣, reflecting the non-stimulated cell level, remained in the normal ranges (data not shown).
To evaluate whether CD57 + and CD57 − lymphocytes share lytic properties, we sorted CD8
+ and CD8 + CD57 − leukemic cells (patient DC) at day 0 after blood sampling and performed the same four CRAs after a 2 day culture with low doses of rhIL-2 but without any prior CD3 activation. CD8 + CD57 + leukemic cells behave the same as whole PBMC: a high CTL-like lysis but no NK nor LAK cell activities were detected (Figure 1b) . In contrast, a weak but significant lysis of Daudi and K562 target cells was observed together with a strong dose-dependent CTL-like lytic activity when CD8
+ CD57 − lymphocytes were tested as effector cells. The same observations were noted when both sorted populations and total PBMC were tested after a 6 day culture in similar conditions (Figure 1c) . Furthermore, CD8
+ CD57 + cells from leukemic patients were compared with sorted CD8 hi+ CD57 + from BMT recipients (Figure 1b) . Whatever the cell origin, we evidenced in both subsets a strong CTL-like CD3-redirected lysis.
Thus leukemic CD3 + CD8
LGL can develop a lytic program upon cross-linking of the TCR-CD3 complex without prior activation, suggesting that the CD57 + T-LGL act as in vivo activated effector CTL deprived of NK activity while CD57 − cells can mediate both types of cytolysis.
IL-2-dependency of the leukemic CD8
LGL leukemic lymphocytes are IL-2-dependent cells, but have been shown to be CD25 − . The constitutively expressed p75 can form a high affinity receptor when p55 is upregulated upon IL-2 activation. 37 We first observed in short-term (day 3) in vitro cultures of LGL a 7-to 36-fold enhancement in stimulation indexes of 3 H-thymidine incorporation in the presence of increasing concentrations of exogenous rhIL-2 ranging from 20 to 100 U/ml (data not shown). The heterogeneity of the leukemic LGL described above with regards to the CD57 expression raised the question of the LGL subset involved in such dose-dependent rhIL-2 induced proliferation. BrdU Table 2 Comparative flow cytometry analysis of activation and adhesion molecules on CD8 incorporation was then coupled to flow cytometry, allowing us to clearly discriminate which cell population proliferates. Thus, high doses of rhIL-2 were tested on LGL from patient DC, displaying 52% of leukemic CD8 +
CD57
+ and 17% of CD8 +
− cells. The initial stimulus with 100 U/ml rhIL-2 allowed BrdU incorporation in 11.7% of CD8 +
+ lymphocytes, but only in 4% of CD8 +
− cells (Figure 2b ) after a 3 day in vitro culture. In contrast after the same 3 day culture in the absence of rhIL-2, only low if any BrdU incorporation was detected in either CD8
− unstimulated cells (Figure 2a) .
These data suggest that among the CD3 + LGL leukemic cells only the CD57 + subset is immediately sensitive to rhIL-2 activation in short-term cultures.
In vitro growth of the leukemic CD8
We then compared the in vitro growth of leukemic LGL from three patients (MR, AD, DC) over a 3 week in vitro culture using three different stimuli at day 0 of the cultures (Figure 3 , left panel). Initial stimulation with PMA + rhIL-2 (Figure 3a) or high doses of rhIL-2 ( Figure 3b ) produced a similar growth of CD8 hi+ CD57 + cells: while total cell number increased, the CD8 hi+ CD57 + subset percentage was unchanged at day 8, then decreased between day 8 and day 25 together with the total CD8 hi+ population. In contrast, an initial PHA + rhIL-2 stimulus (Figure 3c ) or a CD3 triggering (data not shown) was followed by a dramatic fall of the CD8 hi+ CD57
+ subset as early as day 3 (under 3%) for the three patients tested, together with a strong proportion of cell death. A continuous and pronounced expansion of CD8 hi+ lymphocytes that were negative for CD57 was observed in this case from day 8 to day 25. Of note, these results were noticed as early as day 3 of the three culture systems (data not shown).
The cytotoxic potential developed in vitro in these three independent culture systems ( Figure 3 , right panel) was tested at day 7 of the cultures. After an initial stimulation with PMA + rhIL-2 or high doses of rhIL-2 alone, which both allowed persistence of CD8 +
CD57
+ cells at day 7 (Figure 3a and b, respectively), we observed a similar pattern of cytolysis: in both conditions, the CD3-redirected lysis of P815 cells was more important than the K562 and Daudi target cell lysis, with some inter-patient variations in the two latter cases. The same pattern of lysis was observed after a PHA + rhIL-2 stimulation (Figure 3c ) despite the disappearance of CD8 +
+ lymphocytes at day 7 of this culture system. Therefore, an initial stimulus involving either rhIL-2 alone, the PKC system (with PMA) or the CD3-complex (with PHA) allows either a 2 week persistence of CD8 +
+ LGL or their disappearance. However, these three initial stimuli induce in any case a similar cytotoxic profile predominantly involving a CD3-triggering lysis and independently of the CD57 expression on CD8 + T cells.
Leukemic CD8
hi+ CD57 + LGL but not CD8 hi+ CD57
− cells release an inhibitor of cytotoxic functions
Normal and BMT recipients' CD8 + CD57 + lymphocytes are known to mediate immunoregulatory functions, and they especially have the capacity to block NK cell and CTL activity by releasing a soluble glycoproteic inhibitor of cytotoxic functions (ICF). 19, 29, 35 Indeed NK-mediated lysis was undetectable when whole PBMC were used as effector cells, in contrast with the K562 and Daudi lysis observed when testing sorted CD8 + CD57 − cells. We tested the culture supernatants (SN) from sorted CD8 +
CD57
+ leukemic cells of three patients (AD, DC, DL) for their ability to inhibit a normal LAK cell-mediated lysis. Short-term culture SN from unactivated leukemic CD8 hi+ CD57 + T lymphocytes inhibited a lysis of Daudi target cells in two (DL, DC) cases while the SN from autologous CD8 + CD57 − cells were unable to do so, as shown for patient DC in Figure 4a . This phenomenon was not observed with patient AD's CD8 + CD57 + cell SN. We investigated whether the addition of neutralizing Ab against IFN-␥ and/or IL-4 in the lytic assay could restore the inhibitory effect of patient 
+ T lymphocytes. 35 ICF activity mediated by culture supernatant from CD8
LGL was restored when IL-4, but not IFN-␥ was neutralized (Figure 4b) . Moreover, we also observed in patient DC, the disappearance of the ICF inhibitory activity in CD8 + CD57 + supernatant which was produced after his treatment with IFN-␣ (data not shown).
Altogether, these data showed that clonal CD3 +
CD8
hi+ CD57 + leukemic T lymphocytes but not the CD57 − subset produce an inhibitor of cytotoxic functions similar to the effect we previously described in CD8 + CD57 + T cells from normal and BMT donors.
Discussion
The aim of this study was to shed further light on the immune characteristics of the non-aggressive CD56
LGL leukemic cells which were compared with their postulated normal cell counterparts, ie the CD8 + CD57 + cells expanded after BMT. We showed that CD8 +
CD57
+ leukemic LGL had the functional features of the CD8 +
+ T cells from BMT recipients despite some phenotypic differences between both sources of cells. Although lymphoproliferative LGL diseases display an heterogeneous phenotypic profile, 3, 4, 38, 39 clonal CD3
LGL leukemia is usually characterized by a major expression of HLA-DR and CD45RA, 5,17 a positivity for p75/␤IL-2 receptor and p75/TNF-␣ receptor contrasting with the lack of CD25 and p55/TNF-␣ as shown by single color fluorescence analysis. [2] [3] [4] 39 In addition to previous reports, we show here by three-color analysis an upregulation of adhesion molecules CD58, p150/CD11c and ICAM-1/CD54 on CD8 +
+ leukemic LGL while these molecules are expressed on less than 7% of CD8 +
+ LGL from normal donors and BMT recipients. Thus such hyper-expression of adhesion molecules (CD58, CD11c, CD54) appears to be characteristic of leukemic LGL and might be included in the panel of MoAb used for diagnosis. Adhesion molecules on leukemic LGL might also affect the infiltrating capacities of these cells, presuming differences in their invasive potential. These results are in line with LGL leukemia observed in mice transgenic for HTLV-I Tax, 40 although the involvement of HTLV-I or -II in nonaggressive T cell leukemia remains controversial. 41, 42 Moreover, this upregulation of adhesion molecules is also in accordance with surface overexpression of various late activation markers such as HLA-DR and CD38 and with downmodulation of CD62L. However, contrasting with the adhesion molecules CD58, CD54 and CD11c which are overexpressed only on leukemic LGL, but not on CD8 +
+ cells from BMT, the same profile of activation markers is observed both on monoclonal CD8 +
+ leukemic LGL and on oligoclonal CD8 +
+ cells from BMT recipients. We also find an absence of CD25 and CD71 and a weak expression of CD28 on both CD8 +
+ cells from leukemic patients and BMT recipients. In addition, while normal and BMT recipients' CD8 +
+ cells mainly express CD45RA, but co-express the two CD45 isoforms RA and RO, we show here that the CD45RA + leukemic LGL do not display the CD45RO isoform. Taken together, these results show that CD3
+ leukemic LGL differ from their normal and BMT recipients' counterparts by hyper-expression of CD11c and CD54 and negativity for CD45RO, although sharing activation marker expression with BMT recipients' CD8 +
+ cells. The extended use of immunologic markers has allowed us 
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Figure 3
In vitro growth and cytotoxic potential of leukemic PBMC after three different stimuli. We evaluated in vitro growth over 3 week cultures (left panels) of leukemic LGL from three patients. At day 0 of the culture, cells were stimulated with (a) PMA + rhIL-2 20 U/ml, (b) rhIL-2 100 U/ml, (c) PHA + rhIL-2 20 U/ml. Left panels: percentages ± standard deviation of CD8 hi+ CD57
+ () and CD8 hi+ CD57 − T () cells are expressed according to total PBMC in culture. Right panels: cytotoxic potential of three LGL leukemic patient (DL: grey symbols, DC: white symbols, MR: black symbols) cells were evaluated at day 7 for their cytotoxic properties in these three independent culture systems. Effector cells were tested against 51 Cr-labelled Daudi, K562 and P815 ± anti-CD3 at a killer/target cell ratio of 25/1 in a standard chromium release assay.
to clarify the heterogeneous spectrum of T cells in CD3 + LGL leukemia. Leukemic CD3
+ LGL share with the CD3
− co-existing subset most of the phenotypic markers described above. However, the CD8 +
CD57
+ LGL population is homogeneous with regards to the CD45RA and CD16 positive expressions while negative for CD45RO. In contrast, some heterogeneity in the expression of these markers was observed on CD8 +
− lymphocytes which might be composed of two subsets, CD8 
CD16
− cells in which both CD45 isoforms can be expressed, ie CD45RO and CD45RA.
Functional analysis of leukemic CD8 +
CD57
+ cells allowed us to show for the first time that these CD3 + leukemic LGL are differentiated in vivo in killer T cells capable of developing a CD3-redirected cytotoxic activity, without any pre-stimulation. They share this lytic property with CD8 + CD57 + cells from BMT recipients. The in vitro use of anti-CD3 MoAb mimics antigen stimulation of CTL and therefore demonstrates the capacity of the leukemic LGL CD3-TCR complex to transduce signals involved in the cytolytic processes, although the physiological relevance of such a CD3-redirected lysis is not obvious. The CD3 responsiveness we describe goes hand in hand with the rapid Ca 2+ mobilization in single cell LGL upon interaction with its target cell, 43 and makes it conceivable that anti-CD3 MoAb triggers an intracellular signal resulting in phosphorylation of already expressed LFA-1 whose role in such activated conformation is necessary for target binding. 44 Furthermore, this CD3-triggered lysis is in line with previous reports describing leukemic LGL as positive cells for perforin and TiA-1, specific molecules of T lymphocyte granular structures 7, 8 and for FasL, a marker of activated cells. 10, 11 Of note, these leukemic cells also produce IFN-␥ after CD3 activation; so do LGL cell lines derived from the tail tumors of transgenic mice for Tax protein. 40 On the contrary, as already reported, 32 we show that unstimulated leukemic CD8 
Figure 4
The leukemic CD3 
CD56
− phenotype. However, previous observations also reported that a 24-48 h short-term culture of leukemic PBMC with anti-CD3 5, 6 or a long-term culture with rhIL-2 17 could lead to an NK cell activity. Here, we show in addition, that after an appropriate stimulation of leukemic lymphocytes, the CD3-redirected CTL-like lysis always predominates over the NK activity.
Proliferation of leukemic LGL can be triggered by rhIL-2 through their constitutive p75/IL-2 intermediate affinity receptor despite the initial absence of CD25. 12, 13, 37 In addition, we show here, by using BrdU incorporation, that a 3 day rhIL-2 stimulation induced a better proliferation of CD8 +
CD57
+ leukemic LGL than their CD8
− cell counterpart. The disappearance of the CD57 expression on a longer time scale after 2 weeks is in accordance with the previously described impossibility for CD8 +
CD3
+ leukemic cells to retain the CD57 phenotype in long-term culture for up to 2 months. 17 Furthermore, we show here that PHA induces an even more rapid decrease in CD57 expression, while this phenomenon occurs during the first 2 weeks after rhIL-2 or PMA activation. Such differences in maintaining the CD8 + CD57 + phenotype over time contrasted with the similar cytotoxic activity observed in all types of culture, independently of the CD57 expression.
Unactivated leukemic CD8 hi+ CD57 + T lymphocytes, but not their CD57
− counterpart, produce an inhibitor of cytotoxic functions (ICF) as we previously described for AIDS patients' and BMT recipients' CD8 +
CD57
+ cells. 19, 35, 36 To the best of our knowledge, the evidence of production of ICF by T-LGL leukemic patients' cells provided here has not been reported previously. Further investigations, including biochemical studies, are currently being carried out in order to check if the leukemic and the graft recipients' ICF are the same factor. Nevertheless, the leukemic ICF shares characteristics of the ICF produced by CD8 +
+ cells from BMT recipients since both activities are antagonized by IL4 and/or IFN␥. 35 These observations suggest that the cytotoxic potential of CD3 +
CD8
+ CD57 + leukemic LGL might be inhibited in vivo by ICF production.
In our report, one of the four T-LGL lymphoproliferations studied was observed in a patient with rheumatoid arthritis. However, neither phenotypic nor functional differences were seen when compared with the three other lymphoproliferations, suggesting that these characteristics do not depend on the immunopathological environment but are rather intrinsic properties of the CD3 + leukemic T-LGL. Altogether, these results suggest that clonal CD8 +
CD57
+ leukemic lymphocytes are highly differentiated into poorly proliferating effector CTL, capable of producing an inhibitory factor of cytolysis. Therefore, leukemic CD8 + CD57 + LGL have the functional characteristics of oligoclonal CD8 + CD57 + cells in BMT recipients, which might represent their normal cell counterpart expanded after chronic antigenic stimulation.
